丙型肝炎病毒的血清抗体检测及基因组cDNA扩增

Detection of Serum Antibody to Hqpatitis C Virus and Amplification of Its Genomic cDNA

By using N14 and C100-3, EIA test kits, 1554 blood samples collected from high risk groups of hepatitis C virus (HCV) infection were tested for the presence of anti-HCV. The anti-HCV prevalence was found to be 64.5% in post-transfusion associated hepatitis, 28.6% in hemodialysis patients, 19.1% in liver cirrhosis, 10.5% in hepatocellular carcinoma, 7.3% in clinically diagnosed non A non B hepatitis, 4.1% in paid blood donors and 2.6% in medical staff members, which indicates that HCV infection is very serious in this country. Anti-HCV-N14 seemed to appear in blood earlier than anti-HCV-C100-3, and to have a fair correlation to genomic detection by polymerase chain reaction (PCR). Seroconversion of anti-HCV-N14 can be considered as an important indicator for the judgement on HCV infection and infectivity.